ReviewInternational journal of molecular sciences2020
From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Diagnosis of deep vein thrombosis from γ-butylbetaine and L-carnitine in plasma and urine based on untargeted and targeted metabolomics.Scientific reports · 2025Article
- Review
- Venous thrombosis unchained: Pandora's box of noninflammatory mechanisms.Blood advances · 2025Review
- From Circulating Biomarkers to Polymorphic Variants: A Narrative Review of Challenges in Thrombophilia Evaluation.Journal of clinical medicine · 2025Review
- Apelin-13 as a novel diagnostic laboratory biomarker in thromboembolic disorders: a review of literature with prospective insights.International journal of emergency medicine · 2024Review
- Preliminary clinical analysis and pathway study of S100A8 as a biomarker for the diagnosis of acute deep vein thrombosis.Scientific reports · 2024Article
- Review
- Inflammatory proteins are associated with mortality in a middle-aged diverse cohort.Clinical and translational medicine · 2023Article
- Article
- Prediction of in-hospital death following acute type A aortic dissection.Frontiers in public health · 2023Article
- Stratification of Risk Factors of Lung Cancer-Associated Venous Thromboembolism and Determining the Critical Point for Preemptive Intervention: A Systematic Review With Meta-analysis.Clinical Medicine Insights. Oncology · 2023Review
- Contemporary Biomarkers in Pulmonary Embolism Diagnosis: Moving beyond D-Dimers.Journal of personalized medicine · 2022Review
- Efficacy of CRP in combination with D-dimer in predicting adverse postoperative outcomes of patients with acute Stanford type A aortic dissection.Journal of cardiothoracic surgery · 2022Article
- Global thrombosis test for assessing thrombotic status and efficacy of antithrombotic diet and other conditions.Future science OA · 2022Review
- The Implication of Reactive Oxygen Species and Antioxidants in Knee Osteoarthritis.Antioxidants (Basel, Switzerland) · 2021Review
- Review
- Multiple Facets of Venous Thrombosis.International journal of molecular sciences · 2021Article
- Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review.International journal of molecular sciences · 2021Review
- Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism.Cancer management and research · 2021Review
- Current Challenges in Diagnosis of Venous Thromboembolism.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thrombosis is a common and potentially fatal disease, because of its high morbidity and mortality, especially in hospitalized patients. To establish the diagnosis of venous thrombosis, in the last years, a multi-modality approach that involves not only imaging modalities but also serology has been evolving. Multiple studies have demonstrated the use of some biomarkers, such as D-dimer, selectins, microparticles or inflammatory cytokines, for the diagnosis and treatment of venous thrombosis, but there is no single biomarker available to exclusively confirm the diagnosis of venous thrombosis. Considering the fact that there are some issues surrounding the management of patients with venous thrombosis and the duration of treatment, recent studies support the idea that these biomarkers may help guide the length of appropriate anticoagulation treatment, by identifying patients at high risk of recurrence. At the same time, biomarkers may help predict thrombus evolution, potentially identifying patients that would benefit from more aggressive therapies. This review focuses on classic and novel biomarkers currently under investigation, discussing their diagnostic performance and potential benefit in guiding the therapy for venous thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.